View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsSilver Phoenix Resources 배당 및 자사주 매입배당 기준 점검 0/6핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 18Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022.공시 • Apr 13Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) for approximately CAD 190 million in a reverse merger transaction.Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) (SPR) for approximately CAD 190 million in a reverse merger transaction on April 8, 2022. As a part of transaction, the shareholders of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. will be issued common shares of Silver Phoenix Resources Inc. with an aggregate deemed value of CAD 189 million. The MOU also provides that effective on closing of the Proposed Transaction SPR will, among other things: (i) change its name to a name requested by Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. and acceptable to applicable regulatory authorities; (ii) increase the size of its board of directors to between five and nine and (ii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. On completion of the Proposed Transaction, SPR's Board of Directors and management team will be reconstituted to include Sheldon Croome, Chief Executive Officer; Jeffrey R. Gossain, President and Kevin Mills, Chief Financial Officer. Completion of the Proposed Transaction is subject to a number of conditions, including receipt of all necessary shareholder and regulatory approvals, execution of related transaction documents, approval of the Exchange, disposition of SPR's mining assets, there being no adverse material change in the affairs of the parties and completion of satisfactory due diligence by each of the parties. The MOU shall terminate upon any party notifying the others that it is not satisfied with the results of its due diligence investigation by April 30, 2022. Closing of the Proposed Transaction will take place in the second or third quarter of 2022 and in any event prior to October 31, 2022. Kronos Capital Partners acted as financial advisor to Agmedica Bioscience Inc. with respect to the Proposed Transaction.Board Change • Mar 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Silver Phoenix Resources 배당 수익률 vs 시장SP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SP)n/a시장 하위 25% (CA)1.7%시장 상위 25% (CA)5.5%업계 평균 (Metals and Mining)1.4%분석가 예측 (SP) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/06/27 10:50종가2022/03/30 00:00수익2022/03/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Silver Phoenix Resources Inc.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 18Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022.
공시 • Apr 13Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) for approximately CAD 190 million in a reverse merger transaction.Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) (SPR) for approximately CAD 190 million in a reverse merger transaction on April 8, 2022. As a part of transaction, the shareholders of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. will be issued common shares of Silver Phoenix Resources Inc. with an aggregate deemed value of CAD 189 million. The MOU also provides that effective on closing of the Proposed Transaction SPR will, among other things: (i) change its name to a name requested by Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. and acceptable to applicable regulatory authorities; (ii) increase the size of its board of directors to between five and nine and (ii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. On completion of the Proposed Transaction, SPR's Board of Directors and management team will be reconstituted to include Sheldon Croome, Chief Executive Officer; Jeffrey R. Gossain, President and Kevin Mills, Chief Financial Officer. Completion of the Proposed Transaction is subject to a number of conditions, including receipt of all necessary shareholder and regulatory approvals, execution of related transaction documents, approval of the Exchange, disposition of SPR's mining assets, there being no adverse material change in the affairs of the parties and completion of satisfactory due diligence by each of the parties. The MOU shall terminate upon any party notifying the others that it is not satisfied with the results of its due diligence investigation by April 30, 2022. Closing of the Proposed Transaction will take place in the second or third quarter of 2022 and in any event prior to October 31, 2022. Kronos Capital Partners acted as financial advisor to Agmedica Bioscience Inc. with respect to the Proposed Transaction.
Board Change • Mar 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.